Skip to main content
. 2014 Apr 14;9(4):e94167. doi: 10.1371/journal.pone.0094167

Figure 3. MiRNA signatures differ between tumors with and without the KRAS-variant.

Figure 3

Yellow represents patients without the KRAS-variant, and blue patients with the KRAS-variant.